Adomas Bunevicius1, Edward R Laws2, Mary Lee Vance1,3, Sherry Iuliano2, Jason Sheehan4,5. 1. Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA. 2. Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA. 4. Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA. jps2f@hscmail.mcc.virginia.edu. 5. University of Virginia Health System, Charlottesville, VA, USA. jps2f@hscmail.mcc.virginia.edu.
Abstract
INTRODUCTION: Cushing's disease (CD) is rare disorder that should be adequately managed to optimize long-term prognosis. Treatment of CD is multidisciplinary and often includes surgical resection, adjuvant stereotactic radiosurgery (SRS), and medical treatment. Here we review surgical and radiosurgical treatment strategies for ACTH producing pituitary adenomas. METHODS: A comprehensive literature review was carried out to review remission and recurrence rates, and complications of surgical and SRS treatments of ACTH producing pituitary adenomas. RESULTS: Surgical resection plays a central role in the management of ACTH secreting pituitary adenomas and usually allows rapid endocrine remission that ranges from 69 to 90%. The most common complications after resection include some degree of new hypopituitarism, diabetes insipidus and CSF leak. Devastating complications, such as injury of vascular and neural structures, are very rare. Surgeon experience and adequate pre-operative imaging are important for safe and successful surgery. Endocrine recurrence rates after resection range from 9 to 30%. SRS is often employed for incompletely resected adenomas. Endocrine remission after SRS ranges from 35 to 72%. The most common complication of SRS is new anterior pituitary gland deficiency. Recurrence rates after GKRS range from 18 to 24%. CONCLUSIONS: Transsphenoidal resection of ACTH producing pituitary adenoma is a safe and highly effective procedure for CD in experienced hands. Radiosurgery is more frequently used as treatment of residual and recurrent adenoma and persistent CD. Long-term endocrine and imaging follow-up is important as delayed recurrences and hypopituitarism are not infrequent.
INTRODUCTION:Cushing's disease (CD) is rare disorder that should be adequately managed to optimize long-term prognosis. Treatment of CD is multidisciplinary and often includes surgical resection, adjuvant stereotactic radiosurgery (SRS), and medical treatment. Here we review surgical and radiosurgical treatment strategies for ACTH producing pituitary adenomas. METHODS: A comprehensive literature review was carried out to review remission and recurrence rates, and complications of surgical and SRS treatments of ACTH producing pituitary adenomas. RESULTS: Surgical resection plays a central role in the management of ACTH secreting pituitary adenomas and usually allows rapid endocrine remission that ranges from 69 to 90%. The most common complications after resection include some degree of new hypopituitarism, diabetes insipidus and CSF leak. Devastating complications, such as injury of vascular and neural structures, are very rare. Surgeon experience and adequate pre-operative imaging are important for safe and successful surgery. Endocrine recurrence rates after resection range from 9 to 30%. SRS is often employed for incompletely resected adenomas. Endocrine remission after SRS ranges from 35 to 72%. The most common complication of SRS is new anterior pituitary gland deficiency. Recurrence rates after GKRS range from 18 to 24%. CONCLUSIONS: Transsphenoidal resection of ACTH producing pituitary adenoma is a safe and highly effective procedure for CD in experienced hands. Radiosurgery is more frequently used as treatment of residual and recurrent adenoma and persistent CD. Long-term endocrine and imaging follow-up is important as delayed recurrences and hypopituitarism are not infrequent.
Entities:
Keywords:
Cushing’s disease; Gamma knife; Pituitary adenoma; Radiosurgery; Surgery
Authors: J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: Gautam U Mehta; Dale Ding; Mohana Rao Patibandla; Hideyuki Kano; Nathaniel Sisterson; Yan-Hua Su; Michal Krsek; Ahmed M Nabeel; Amr El-Shehaby; Khaled A Kareem; Nuria Martinez-Moreno; David Mathieu; Brendan McShane; Kevin Blas; Douglas Kondziolka; Inga Grills; John Y Lee; Roberto Martinez-Alvarez; Wael A Reda; Roman Liscak; Cheng-Chia Lee; L Dade Lunsford; Mary Lee Vance; Jason P Sheehan Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Oskar Ragnarsson; Daniel S Olsson; Dimitrios Chantzichristos; Eleni Papakokkinou; Per Dahlqvist; Elin Segerstedt; Tommy Olsson; Maria Petersson; Katarina Berinder; Sophie Bensing; Charlotte Höybye; Britt Edén Engström; Pia Burman; Lorenza Bonelli; Cecilia Follin; David Petranek; Eva Marie Erfurth; Jeanette Wahlberg; Bertil Ekman; Anna-Karin Åkerman; Erik Schwarcz; Ing-Liss Bryngelsson; Gudmundur Johannsson Journal: Pituitary Date: 2019-04 Impact factor: 4.107
Authors: L Andereggen; J Frey; R H Andres; M M Luedi; M El-Koussy; H R Widmer; J Beck; L Mariani; R W Seiler; E Christ Journal: J Endocrinol Invest Date: 2021-04-13 Impact factor: 4.256